Dendreon to pursue sale: Bloomberg

Troubled Dendreon (DNDN) is reportedly seeking a buyer.

Bloomberg said Friday the company has hired JPMorgan to assist in the process.

The shares are down 54% YTD and are off around 44% since early August when the outlook for Provenge sales darkened (see here and here).

From other sites
Comments (9)
  • Bill Maurer
    , contributor
    Comments (7436) | Send Message
    Nice of them to do this after shares have fallen from $17 to $2.50, and as noted above, down 44% since early August.
    26 Oct 2013, 10:40 PM Reply Like
  • Patent News
    , contributor
    Comments (1475) | Send Message
    who wants to buy this clunker?


    best of luck. ha!
    26 Oct 2013, 10:53 PM Reply Like
  • Richard0623
    , contributor
    Comments (178) | Send Message
    Lol what a joke. Why would anyone want to buy them? They've had plenty of chances to sell themselves. In fact, I wouldn't be surprised if the stock was down going forward because this should prove the sales numbers are disappointing again and they are giving up hope. Oh and btw, I own a couple hundred shares, so I'd prefer a sale, or any sort of positive increase in revenue, or for the company to do a single positive things to increase its stock price. But since I know they can't do a cotton picking thing right, DNDN will die before being acquired. Maybe J&J will acquire them just to kill them the next day and rub it in DNDN's face
    27 Oct 2013, 12:10 AM Reply Like
  • McBride
    , contributor
    Comments (410) | Send Message
    Why people with such a negative view hold ANY shares at all, just mystifies me. If there is no room for forward progress, Richard0623, why did you buy it? If they can't do a SINGLE positive thing, and the sales numbers have been so disappointing for so long, I suggest you sell all your shares today.
    28 Oct 2013, 09:14 AM Reply Like
  • Magnetfeldfredy
    , contributor
    Comments (43) | Send Message
    Dendreon has the best in class product with Provenge in the pc-space with EU-approval, big pharma can make a blockbuster product with the world-wide rights that belongs alone to Dendreon, not like Medivation!
    With positive sequenz-studies Dendreon can come back to double digits share price!
    27 Oct 2013, 02:29 AM Reply Like
  • L.A.RICK
    , contributor
    Comments (80) | Send Message
    As an investment banker who's spent 35 years on Wall Street doing deals, I'll be buying DNDN stock on Monday for the first time. An acquisition of this type of product is desired by big pharma because so many of their proprietary drugs are coming off patent.


    This is a no-brainer for a $5+ share price takeover, which is pocket change for the mainstream drug companies. They can market the drug at half of the going price and still make a fortune. The major problem with DNDN was the incredibly stupid management!
    27 Oct 2013, 10:01 AM Reply Like
  • KJP712
    , contributor
    Comments (472) | Send Message
    Check out the short interest in this stock.Many on Wall Street will notice and see the potential for trades on the different possibilities.Emotion goes out the window when a short squeeze takes place.JNJ is a potential buyer eliminating a rival or keeping another big player from acquiring it.Things can escalate starting Monday.
    27 Oct 2013, 10:47 AM Reply Like
  • 166649
    , contributor
    Comments (382) | Send Message
    Provenge does work. Many swear by it. Europe has approved the drug.The Co. had trouble with marketing due to under-capitalization


    The problem was it is $90K per treatment. However, Medicare did decide to cover it and supplemental coverages has also kicked in.


    There are no cancer vaccines that been proven to be effective. At some point some major company may decide to take it over....again DNDN has just been under-capitalized and the cost was prohibitive at $90K for a long period of time. Now that Medicare coverage has kicked in and a larger company will obviously have no capitalization issues, why not buy DNDN?
    27 Oct 2013, 10:59 AM Reply Like
  • wired4acure
    , contributor
    Comments (46) | Send Message
    not just a one trick pony- future applications based on the use of their platform have big future. Personalized medicine is going to me the medical rule in the near future-


    Gold's loudly stated strategy to go it alone and shun all partners made them a target for BP. This an other poor management decisions like over building hurt the stock as it gained initial FDA approval. The overhead and marketing issues have been addressed. The science and patents are most certainly marketable and coveted. A loud announcement of availability will trigger a positive response with European and international audiences. Not all suitors are apt to cut their noses off to save face on this one. GLTAL
    28 Oct 2013, 08:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs